Fig. 1

Effects of TRCQT with aspirin against thromboembolic stroke in rats. The infarct volume was measured after 30 days of treatment with TRCQT, aspirin or a combination of TRCQT and aspirin after middle cerebral artery occlusion (MCAO). A TTC (2,3,5-triphenyltetrazolum chloride solution) staining of the brain slices showing the infarct areas in the sham (a), thromboembolic occlusion-induced untreated (b), aspirin (5 mg/kg) (c), TRCQT (0.5 g/kg) (d) and combination-treated groups (e). B Histogram showing the quantification of the infarct volumes in the sham, thromboembolic occlusion-induced untreated, aspirin, TRCQT and combination-treated groups. These data represent the mean ± SD of three independent experiments. ^### P < 0.001 compared with sham group, ***P < 0.001 compared with the thromboembolic occlusion-induced untreated group (n = 5)